Link: Reuters report on Lillys May 21, 2026 retatrutide obesity trial update: Retatrutide: Lillys Triple-G Obesity Drug Moves Closer to Approval 21/5/26 Eli Lilly has reported major Phase 3 obesity-trial results for retatrutide, an investigational once-weekly injectable drug acting on GIP, GLP-1 and glucagon receptors
However, a formal work-up and diagnosis were never done
The practical guidance most clinicians give: don't overthink it
Moreover, in DNA methylation alterations of tumor cells induced by GLP-1RAs, studies have demonstrated that during breast cancer progression, tumor suppressor genes such as ESR1, CDH1, and ADAM33 are downregulated due to hypermethylation alterations in their promoter regions
For many people, that means less food noise, fewer large swings in hunger, and a more sustainable platform for long-term behavior change